1 孙瑞元, 郑青山.数学药理学新论[M].北京:人民卫生出版社, 2004:486.
2 张强, 李屯, 廖工铁, 刘定远.NONMEM 法:从临床常规化验数据计算群体药动学参数[J].中国医院药学杂志,1994;14(7):330-3
3 Sheiner LB, Beal SL.Pharmacokinetic parameter estimates from several least squares procedures:superiority of extended least squares[J].J Pharmacokinet Biopharm, 1985;13 (2):185
4 Schuttler J, Lhmsen H.Population pharmacokinetics of propofol [J].Anesthesiology, 2000;92(3):727-38
5 胡敏, 张静华, 孙鹤, 施孝金, 钟明康.群体药动学原理及NONMEM 法数据分析[J].药学服务与研究, 2002;2(4):227-30
6 KarlssonMO, Sheiner LB.The importance of modeling interoccasion variability in population pharmacokinetic analyses[J].J Pharmacokin Biopharm, 1993;21(6):735-50
7 Vozeh S, Steimer JL, RowlandM, Morselli P, Mentre F, Balant LP, et al.The use of population pharmacokinetics in drug development[J].Clin Pharmacokinet, 1996;30(2):81-95
8 FDA.Guidance for industry population pharmacokinetics[EB OL].http: www.fda.gov cder guidance index.htm, 1999-2/2004-12
9 Furuya A, Kato N, Jingu S, Akimoto M, Higuchi S, Suwa T, et al.Population pharmacokinetics and pharmacodynamics of TS-943 for selective nonpeptide platelet glycoprotein IIb IIIa receptor antagonist in normal healthy subjects[J].Clin Pharmacol Ther, 2000;67(5):489-97
10 Antal EJ, Grasela TH, Smith RB.An evaluation of population pharmacokinetics in therapeutic, trials, part Ill, prospective data collection versus retrospective data assembly [J].Clin Pharmacol Ther, 1989;46(5):552-9
11 Grasela TH, Antal EJ, Townsend RJ, Smith RB.An evaluation of population pharmacokinetics in therapcutic trials, part I, comparison of methodologies[J].Clin Pharmacol Ther, l986;39(6):605-12
12 Wade JR, Kelman Aw, Howie CA, Whiting B.Effect of Misspecification of the absorption process on subsequent parameter estimation in population analysis[J].J Pharmacokin Biopharm, 1993;21(2):209-222
13 Honghui Z, Les C, Henry L, Ute B, De V, Gail E, et al.Population pharmacokinetics toxicodynamics (PK TD) relationship of sam486a in phase 1 studies in patients with advanced cancers [J].J Clin Pharmacol, 2000;40(3):275-83
14 周燕, 芮建中, 谈恒山, 蔡明虹, 凌树森.NONMEM 法估算地高辛相对生物利用度和药动学参数[J].中国医院药学杂志, 2000;20(7):393-6
15 Graves DA, Chang IH.Application of NONMEM to routine bioavailability data[J].J Pharmacokin Biopharm, 1990;18(2): 145-60
16 Comets E, Mentre F, Grass P, Kawai R, Marbach P, Vonderscher J.Population pharmacodynamics analysis of octreotide in acromegalic patients[J].Clin Pharmacol Ther, 2003;73(1): 95-106
17 Ouellet D, Bockbrader HN, Wesche DL, Shapiro DY, Garofalo E.Population pharmacokinetics of gabapentin in infants and children[J].Epilepsy Res, 2001;47(3):229-41 |
